Document Detail

Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro ).
MedLine Citation:
PMID:  12082199     Owner:  NLM     Status:  MEDLINE    
Studies of patients scheduled for percutaneous coronary intervention with acute coronary syndrome have shown that the addition of intravenous glycoprotein (GP) IIb/IIIa inhibitors to aspirin and heparin is associated with a reduction in death or myocardial infarction compared to therapy with aspirin and heparin alone. The principle safety issue with GP IIb/IIIa inhibitors is the risk of bleeding, as the potent antiplatelet effect of these drugs may adversely affect hemostasis. In addition, antagonists of GP IIb/IIIa may increase the risk of thrombocytopenia. We report a case of abciximab-induced severe thrombocytopenia which led to fatal intra-cranial hemorrhage.
Shivang M Trivedi; Jacob Shani; Gerald Hollander
Related Documents :
8641009 - Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-...
10101569 - A case report of heparin resistance due to acquired antithrombin iii deficiency.
8419269 - The role of dipyridamole in the therapy of vascular disease.
9589829 - Antiplatelet therapy in atherosclerotic cardiovascular disease.
946309 - Selective coronary arteriography. risk in a community hospital.
319319 - An intervention study-the aspirin myocardial infarction study.
17347689 - Newborn hearts are at greater 'metabolic risk' during global ischemia--advantages of co...
19897709 - Bradykinin and thromboxane a2 reciprocally interact to synergistically stimulate cardia...
12810089 - Increased severity of reperfusion arrhythmias in mouse hearts lacking histamine h3-rece...
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  The Journal of invasive cardiology     Volume:  14     ISSN:  1042-3931     ISO Abbreviation:  J Invasive Cardiol     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-06-25     Completed Date:  2002-08-15     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  8917477     Medline TA:  J Invasive Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  423-5     Citation Subset:  IM    
Division of Cardiology, Maimonides Medical Center, Brooklyn, NY 11219, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon, Coronary / methods
Antibodies, Monoclonal / administration & dosage,  adverse effects*
Combined Modality Therapy
Coronary Angiography
Coronary Stenosis / radiography,  therapy*
Fatal Outcome
Immunoglobulin Fab Fragments / administration & dosage,  adverse effects*
Infusions, Intravenous
Intracranial Hemorrhages / chemically induced*
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects*
Severity of Illness Index
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of the X-SIXER catheter system in the treatment of acute thrombotic coronary occlusion.
Next Document:  Thrombotic occlusion of the left main coronary artery during coronary angiography.